Bild 1 von 1

Standardbild

Dual Drug Delivery System Containing Ornidazole and Ofloxacin Dasharath M. Patel - Bild 1 von 1

Dual Drug Delivery System Containing Ornidazole And Ofloxacin von Dasharath M. Patel (2015, Taschenbuch)

buch-mimpf (20174)

100% positive Bewertungen

Preis:

€ 54,90

(inkl. MwSt.)

Kostenloser Versand

Lieferung ca. Di, 22. Jul - Sa, 26. Jul

Rücknahme:

1 Monat Rückgabe. Käufer zahlt Rückversand. Wenn Sie ein eBay-Versandetikett verwenden, werden die Kosten dafür von Ihrer Rückerstattung abgezogen. Für eBay Plus-Mitglieder ist der Rückversand im Inland kostenlos. Mehr erfahren.

Artikelzustand:

Neu

Titel: Dual Drug Delivery System Containing Ornidazole and Ofloxacin, Untertitel: Colon Targeted Ornidazole and Sustained Release Ofloxacin Pellets for Treatment of Amoebic Dysentery, Einband: Taschenbuch, Autor: Dasharath M. Patel, Verlag: LAP LAMBERT Academic Publishing, Sprache: Englisch, Seiten: 108, Maße: 220x150x7 mm, Gewicht: 179 g, Verkäufer: buch-mimpf.

Sammeln Sie 55 Punkte | Mehr erfahrenzu eBay Plus-Punkten - wird in neuem Fenster oder Tab geöffnet

Über dieses Produkt

Produktinformation

This book describes the design and evaluation of multiple unit pellet system (MUPS) for dual drug delivery i.e. sustained release ofloxacin and colon targeted ornidazole to treat dysentery as an alternative to conventional formulations. It involves a detailed procedural aspects for formulation and coating of pellets with Eudragit RS100 and Eudragit S100. It also describes an in vitro evaluation of pellets for various parameters along with in vivo colon targeting. The book describes the DOE approach for the Ofloxacin sustained release pellets optimization using full factorial design. It describes the modeling of dissolution kinetics. In vivo X-ray images showed similarity with in vitro release profile that pellets disappear only after reaching to colon. Multiple unit pellet system provided extended release of ofloxacin and delivery of ornidazole to colon providing an alternative for conventional formulations in treatment of amoebic dysentery with reduced side effects. Drug-excipient compatibility study revealed no interaction between drug and excipients. Optimized formulation showed good stability at accelerated environmental conditions.